?AUTOIMMUNE DISEASES GROUP Through this Funding Opportunity Announcement, the NIAID Division of Allergy, Immunology and Transplantation (DAIT) intends to consolidate its funding for multiple, independent Statistical and Clinical Coordinating Centers (SACCCs) into a single multi-component cooperative agreement, presumably to reduce costs and increase efficiency and standardization across research consortia. This new program will fund a single SACCC or Center to support DAIT research in the areas of asthma and allergic diseases, autoimmune diseases, and transplantation, and in the area of autoimmune diseases research, this Center will provide support to 3 consortia?the Autoimmunity Centers of Excellence (ACE), Hematopoietic Stem Cell Therapy Consortium (HSCTC), and the autoimmune diseases component of the Immune Tolerance Network (ITN). Within the Center, support for these 3 consortia will be organized under 1 group?the Autoimmune Diseases Group (ADG). The objective of the ADG is to provide excellent and efficient study coordination support services across the 3 autoimmune diseases research consortia. To accomplish this objective, RhoFED aims to (1) provide staff experienced in autoimmune disease research conducted by DAIT-supported consortia and to organize these staff in an administrative structure that manages resources efficiently, is responsive to the needs of the research consortia and DAIT, and facilitates communication and collaboration; (2) provide experienced scientists and statisticians who, in collaboration with clinical investigators and senior DAIT officials, design and analyze studies across the full scope of research in autoimmune diseases; (3) facilitate the development, review, and revision of initial and successive drafts of protocols and protocol-related documents through dedicated ADG protocol teams; and (4) provide study initiation and study management functions that are required for the efficient and ethical conduct of studies. Because RhoFED is currently the SACCC for ACE, HSCT, and the Statistical Data Coordinating Center (SDCC) for ITN, RhoFED is well suited to provide consolidated SACCC support across the 3 consortia. And, by providing staff with experience in supporting autoimmune disease research and an administrative infrastructure designed to enhance collaboration between parties and support agile and effective resource management, we believe that support of these 3 consortia through the newly formed Center and the ADG will directly contribute to the achievement of the DAIT objective to better understand, treat, and prevent autoimmune diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Program Project or Center with Complex Structure Cooperative Agreement (UM2)
Project #
1UM2AI117870-01
Application #
8892721
Study Section
Special Emphasis Panel (ZAI1-PA-I (J2))
Project Start
2015-05-07
Project End
2022-04-30
Budget Start
2015-05-07
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$2,625,799
Indirect Cost
$974,353
Name
Rho Federal Systems Division, Inc.
Department
Type
DUNS #
362726007
City
Chapel Hill
State
NC
Country
United States
Zip Code
27517
Calabrese, Sarah K; Earnshaw, Valerie A; Krakower, Douglas S et al. (2018) A Closer Look at Racism and Heterosexism in Medical Students' Clinical Decision-Making Related to HIV Pre-Exposure Prophylaxis (PrEP): Implications for PrEP Education. AIDS Behav 22:1122-1138
Gill, Michelle A; Liu, Andrew H; Calatroni, Agustin et al. (2018) Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 141:1735-1743.e9
Wildfire, Jeremy; Bailey, Ryan; Krouse, Rebecca Z et al. (2018) The Safety Explorer Suite: Interactive Safety Monitoring for Clinical Trials. Ther Innov Regul Sci 52:696-700
Simpson, Eric L; Villarreal, Miguel; Jepson, Brett et al. (2018) Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. J Invest Dermatol 138:2224-2233
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
Gergen, Peter J; Mitchell, Herman E; Calatroni, Agustin et al. (2018) Sensitization and Exposure to Pets: The Effect on Asthma Morbidity in the US Population. J Allergy Clin Immunol Pract 6:101-107.e2
du Toit, George; Sayre, Peter H; Roberts, Graham et al. (2018) Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort. J Allergy Clin Immunol 141:1343-1353
Keever-Taylor, Carolyn A; Heimfeld, Shelly; Steinmiller, Kaitlyn C et al. (2017) Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. Biol Blood Marrow Transplant 23:1463-1472
Esquivel, Ann; Busse, William W; Calatroni, Agustin et al. (2017) Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med 196:985-992
Lawson, K; Bahnson, H T; Brittain, E et al. (2017) Letter of response to Greenhawt et al. 'LEAPing Through the Looking Glass: Secondary Analysis of the Effect of Skin Test Size and Age of Introduction on Peanut Tolerance after Early Peanut Introduction'. Allergy 72:1267-1271

Showing the most recent 10 out of 33 publications